A Phase I/2 Study of Ixazomib for Chronic Graft-Versus-Host Disease (cGVHD) Prophylaxis After Allogeneic Transplantation (alloHCT).

Biology of Blood and Marrow Transplantation - Netherlands
doi 10.1016/j.bbmt.2018.12.213

Related search